Background
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a life-saving intervention for severe acute respiratory distress syndrome (ARDS), including that caused by COVID-19. Weaning from VV-ECMO is a complex process, often complicated by persistent right ventricular (RV) dysfunction, which poses significant challenges for decannulation decisions.
Methods
This paper synthesizes expert clinical perspectives on VV-ECMO weaning criteria, focusing on RV assessment, sweep gas trial protocols, and the utility of inhaled pulmonary vasodilators. Two verified critical care physicians contributed detailed protocols and insights to a community peer-review platform, which subsequently garnered 84 peer votes, establishing a consensus.
Results
Findings suggest that mild residual RV dysfunction may be acceptable for decannulation if gas exchange and hemodynamic stability are maintained, with RV function often improving post-ECMO removal. Staged sweep gas trials, extending up to 6 hours, are advocated, alongside continuous monitoring of respiratory mechanics, gas exchange, and hemodynamic parameters. The use of inhaled iloprost as a bridging therapy for residual pulmonary hypertension was also discussed.
Conclusions
This consensus initiative provides a pragmatic framework for VV-ECMO weaning in patients with COVID-19 ARDS and RV dysfunction, emphasizing individualized patient assessment and a multidisciplinary approach. It underscores the need for further research to standardize weaning protocols and optimize outcomes in this challenging patient population.
["Right Ventricular Dysfunction: Mild persistent RV dilation (RVEDD/LVEDD up to 1.2) with stable TAPSE (>12mm) and hemodynamics may be acceptable for decannulation if gas exchange is adequate. However, worsening RV dysfunction during sweep 0 trials is an absolute contraindication.","Staged Sweep Gas Trials: Implement a staged sweep gas trial protocol, gradually reducing sweep flow to 0 L/min over several days, with the final sweep 0 trial lasting 4-6 hours, including a spontaneous breathing component.","Comprehensive Monitoring: During sweep trials, continuously monitor respiratory rate (<30), P/F ratio (>150-200 on FiO2 <0.5), stable lactate, and absence of new vasopressor requirements. Consider serial RV strain biomarkers (e.g., NT-proBNP) for additional objective assessment.","Inhaled Iloprost as Bridge: For patients with residual pulmonary hypertension, consider a trial of inhaled iloprost (started 24 hours pre-decannulation and continued for 48-72 hours post) as a bridging therapy to reduce RV afterload without systemic hemodynamic compromise, though evidence is primarily anecdotal.","Pre-Decannulation DVT Screening: Perform ultrasound screening of femoral and internal jugular veins for ECMO-associated deep vein thrombosis (DVT) prior to decannulation, as DVT at cannula sites is common and impacts post-decannulation anticoagulation planning."]
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) has emerged as a critical life-support modality for patients with severe acute respiratory distress syndrome (ARDS) refractory to conventional mechanical ventilation, particularly during the COVID-19 pandemic [1, 2]. Despite its life-saving potential, VV-ECMO is associated with significant morbidity and mortality, and the process of weaning and decannulation is fraught with clinical complexities [3]. Successful decannulation requires careful assessment of pulmonary recovery, systemic hemodynamics, and the patient's overall physiological reserve. A major challenge encountered during VV-ECMO weaning is the management of right ventricular (RV) dysfunction, which can be exacerbated by the underlying ARDS, mechanical ventilation strategies, and the physiological changes associated with ECMO support [4].
ARDS, irrespective of etiology, frequently leads to pulmonary hypertension and RV dysfunction due to hypoxic pulmonary vasoconstriction, direct lung injury, and the effects of positive pressure ventilation [5]. In the context of COVID-19 ARDS, the inflammatory milieu and potential for microthrombosis may further contribute to pulmonary vascular dysfunction and RV strain [6]. While VV-ECMO primarily supports gas exchange, it can indirectly reduce RV afterload by improving oxygenation and mitigating hypercapnia, thereby alleviating hypoxic pulmonary vasoconstriction. However, persistent RV dysfunction, even with improving lung mechanics, can complicate the decision-making process for decannulation, as the RV must be capable of handling the entire cardiac output against potentially elevated pulmonary vascular resistance once ECMO support is withdrawn.
Currently, standardized, evidence-based guidelines for VV-ECMO weaning, particularly concerning the optimal management of RV dysfunction and the precise methodology for sweep gas trials, remain an area of active investigation and clinical variability [3, 7]. The Extracorporeal Life Support Organization (ELSO) provides general recommendations, but specific protocols for addressing nuanced issues like persistent mild RV dysfunction or the utility of adjunctive therapies during the decannulation phase are often left to institutional discretion and expert consensus. This variability underscores a significant knowledge gap in critical care practice, potentially leading to prolonged ECMO durations, increased complications, or premature decannulation failures.
This paper aims to bridge this knowledge gap by synthesizing expert clinical insights from a peer-reviewed community discussion regarding VV-ECMO weaning in a patient with severe COVID-19 ARDS and persistent RV dysfunction. By analyzing the approaches of experienced critical care physicians, we seek to delineate current best practices, identify areas of consensus and divergence, and provide a pragmatic framework for managing these complex patients. The focus will be on the criteria for accepting RV dysfunction, the methodology for sweep gas trials, and the role of inhaled pulmonary vasodilators as a bridging strategy during decannulation.
The central clinical inquiry addressed in this consensus initiative pertains to the optimal management of veno-venous extracorporeal membrane oxygenation (VV-ECMO) weaning in patients with severe COVID-19 acute respiratory distress syndrome (ARDS) complicated by persistent right ventricular (RV) dysfunction. Specifically, the discussion focused on three critical aspects:
This academic paper is derived from a structured clinical question and answer discussion facilitated through a specialized online community peer-review platform (tachyDx). The platform is designed to foster evidence-based clinical discourse among verified medical professionals, ensuring the credibility and expertise of contributing authors. The initial clinical scenario, detailing a 38-year-old male on VV-ECMO for severe COVID-19 ARDS with persistent right ventricular (RV) dysfunction, was posed by Dr. Elena Vasquez, a specialist in Critical Care and ECMO from Hospital Universitario La Paz, Madrid.
Two highly experienced critical care physicians provided comprehensive responses to the posed questions. Dr. Rajesh Iyer, a specialist in Pulmonary & Critical Care from CMC Vellore, provided the accepted answer, outlining a detailed protocol based on his institution's practice. Dr. Vasquez subsequently shared her institution's protocol for comparison, enriching the discussion with diverse expert perspectives. All contributing physicians undergo a rigorous verification process to confirm their credentials and specialty expertise, ensuring that the insights provided are from qualified medical professionals.
The clinical discussion was subjected to community peer review, garnering 84 peer votes. This voting mechanism serves as a form of collective validation, indicating the perceived clinical relevance and soundness of the proposed approaches within the critical care community. While not a formal systematic review or randomized controlled trial, this methodology allows for the rapid dissemination and synthesis of real-world clinical practices and expert opinions on challenging management scenarios, reflecting a form of 'clinical consensus' derived from a broad base of experienced practitioners. The synthesis presented herein integrates these expert opinions, contextualizes them with existing medical literature, and aims to provide a structured framework for clinical decision-making.
The clinical scenario presented a 38-year-old male on VV-ECMO for 18 days due to severe COVID-19 ARDS, demonstrating improving lung compliance (from 12 to 28 mL/cmH2O) and gas exchange (P/F ratio 185 on FiO2 0.4, PEEP 10, TV 350 mL, with minimal ECMO support). The primary challenge was persistent RV dilation (RVEDD/LVEDD 1.1) with impaired TAPSE (14mm) and elevated estimated PA systolic pressure (52 mmHg), which remained unchanged for five days despite pulmonary improvement.
Regarding the management of persistent RV dysfunction, a consensus emerged that complete RV normalization is not an absolute prerequisite for decannulation. Dr. Iyer's approach explicitly states that decannulation can proceed with mild RV dilation if gas exchange is adequate on sweep 0 for 4+ hours and the patient remains hemodynamically stable without vasopressor escalation [1]. This rationale is supported by the observation that RV function often improves spontaneously over days to weeks post-ECMO removal, a finding corroborated by ELSO registry data [1]. Dr. Vasquez's institutional protocol further supports this, having successfully decannulated 9 out of 28 patients with mild RV dysfunction (RVEDD/LVEDD 0.9-1.2), with 7 of these patients achieving RV normalization by 30-day echocardiography [2]. A critical caveat, however, is the absolute contraindication to decannulation if new or worsening RV dysfunction (e.g., decreasing TAPSE or increasing tricuspid regurgitation jet velocity) is observed during sweep 0 trials, indicating an inability of the RV to manage full cardiac output without ECMO support [2]. Both experts emphasized the importance of continuous hemodynamic monitoring, including CVP trends and vasopressor requirements, during weaning trials.
The sweep gas trial protocols exhibited some variation but shared core principles of gradual reduction and close monitoring. Dr. Iyer described a staged approach over three days: Day 1 with sweep 1 L/min for 2 hours, Day 2 with sweep 0 L/min for 4 hours, and Day 3 with sweep 0 for 6 hours incorporating a spontaneous breathing component [1]. Decannulation is planned for Day 4 if all trials are tolerated. Key monitoring parameters included respiratory rate (<30), P/F ratio (>150 on FiO2 <0.5), stable lactate, and no new vasopressor requirements. Dr. Vasquez's protocol similarly mandates sweep 0 toleration for 6 hours, with additional criteria including a P/F ratio >200 on FiO2 <0.5 and PEEP <12, and a TAPSE >12mm [2]. Her protocol uniquely incorporates RV strain biomarkers, specifically serial NT-proBNP, requiring a downward trend over 48 hours as an indicator of improving RV stress [2].
Concerning the use of inhaled iloprost, both physicians acknowledged its potential utility. Dr. Iyer reported using it in four cases as a bridge, initiated 24 hours pre-decannulation and continued for 48-72 hours post-decannulation [1]. He highlighted its logical benefit in addressing residual pulmonary hypertension without systemic hemodynamic compromise, although acknowledging the evidence as anecdotal. Dr. Vasquez's protocol did not explicitly detail iloprost use but the discussion indicates its consideration in cases of persistent pulmonary hypertension. The consensus suggests that while not standard, it represents a plausible adjunctive therapy for specific patients.
An important clinical pearl emphasized by Dr. Iyer was the pre-decannulation screening for ECMO-associated deep vein thrombosis (DVT), particularly at cannula sites (femoral and internal jugular veins) [1]. DVT incidence can be as high as 40% in ECMO patients, and its detection significantly impacts post-decannulation anticoagulation strategies. This highlights the importance of a comprehensive assessment beyond cardiopulmonary parameters.
| Approach | Evidence Level | Key Advantages | Limitations | Source |
|---|---|---|---|---|
| RV Dysfunction & Decannulation | ||||
| Accept mild RV dysfunction if stable gas exchange & hemodynamics | Expert Consensus, ELSO Registry Data, Institutional Cohort Data | Avoids prolonged ECMO, RV often improves post-decannulation | Risk of RV failure post-decannulation if dysfunction is underestimated | Dr. Iyer [1], Dr. Vasquez [2] |
| Mandate RV normalization | Not supported by consensus | Potentially safer RV transition | Prolongs ECMO duration, may be unnecessary | Implied by question, not supported |
| Sweep Gas Trial Protocol | ||||
| Staged approach (e.g., 1L/min then 0L/min for 4-6 hours) | Expert Consensus, Institutional Protocols | Gradual assessment, allows for patient adaptation, comprehensive monitoring | Time-consuming, requires dedicated staffing, variability in specific durations | Dr. Iyer [1], Dr. Vasquez [2] |
| Short (1-hour) sweep 0 trials | Not supported by consensus | Faster assessment | May miss delayed decompensation | Implied by question, not supported |
| Adjunctive Therapy | ||||
| Inhaled Iloprost as bridge | Anecdotal/Logical | Targets pulmonary hypertension without systemic effects | Limited randomized controlled trial data, requires specialized delivery | Dr. Iyer [1] |
| Monitoring & Ancillary | ||||
| RV strain biomarkers (NT-proBNP) | Institutional Protocol, Emerging Evidence | Provides objective measure of RV stress | Not universally adopted, interpretation requires experience | Dr. Vasquez [2] |
| Pre-decannulation DVT screening | Expert Recommendation, Observational Data | Informs post-decannulation anticoagulation, prevents complications | Adds to diagnostic burden, not always standard practice | Dr. Iyer [1] |
The synthesis of expert opinions regarding VV-ECMO weaning in COVID-19 ARDS patients with persistent RV dysfunction reveals several key areas of consensus and highlights the pragmatic approach often necessitated in critical care. The patient scenario, characterized by improving lung mechanics but static RV impairment, represents a common dilemma. The prevailing consensus to accept mild RV dysfunction prior to decannulation, provided gas exchange and hemodynamic stability are maintained, aligns with emerging clinical observations and the understanding of RV recovery post-ECMO [8]. The ELSO registry data, as referenced by Dr. Iyer, provides a broad observational basis for this practice, suggesting that the RV's ability to adapt to full cardiac output often improves once the mechanical and inflammatory burdens associated with severe ARDS and ECMO are alleviated [1, 3]. This approach minimizes prolonged ECMO duration, which is itself associated with increased risks of infection, bleeding, and neurological complications [9]. However, the critical caveat articulated by Dr. Vasquez regarding the absolute contraindication of worsening RV function during sweep 0 trials underscores the importance of dynamic assessment and individualized decision-making [2].
The proposed sweep gas trial protocols, while varying in their precise staging and duration, share the fundamental principle of a gradual, monitored reduction in ECMO support. Both Dr. Iyer and Dr. Vasquez advocate for trials extending beyond 1 hour, with Dr. Iyer's protocol spanning multiple days and Dr. Vasquez's requiring 6 hours of sweep 0 toleration [1, 2]. This extended observation period is crucial for detecting delayed cardiopulmonary decompensation, which may not manifest during shorter trials. The comprehensive monitoring parameters, including respiratory rate, P/F ratio, vasopressor requirements, and lactate levels, are consistent with established critical care practices for assessing readiness for ventilatory liberation and hemodynamic stability [10]. The incorporation of RV strain biomarkers like NT-proBNP in Dr. Vasquez's protocol represents a valuable addition, offering an objective, quantitative measure of RV stress that complements echocardiographic findings and may enhance the precision of decannulation decisions [2, 11].
The discussion surrounding inhaled iloprost as a bridging therapy for residual pulmonary hypertension is particularly pertinent. Pulmonary hypertension is a common sequela of severe ARDS, contributing significantly to RV dysfunction and increasing the risk of post-decannulation RV failure [5]. While the evidence for inhaled iloprost in this specific context remains anecdotal, its physiological rationale is sound. As a selective pulmonary vasodilator, iloprost can reduce pulmonary vascular resistance, thereby decreasing RV afterload, without causing significant systemic hypotension [12]. This targeted approach may facilitate a smoother transition off ECMO in patients with persistent pulmonary hypertension, warranting further investigation through prospective studies. Other inhaled pulmonary vasodilators, such as nitric oxide, have also been explored in ARDS and ECMO weaning, with mixed results [13].
Finally, the emphasis on pre-decannulation screening for ECMO-associated deep vein thrombosis (DVT) highlights a crucial, often overlooked aspect of patient safety. The high incidence of DVT, particularly at cannula sites, necessitates careful consideration for post-decannulation anticoagulation strategies [14]. This proactive screening can prevent potentially catastrophic embolic events and guide appropriate thromboprophylaxis, underscoring the holistic approach required for successful ECMO management. The variability in institutional protocols, as evidenced by the differences between the two contributing physicians, suggests a need for further standardization through multicenter trials and updated guidelines to optimize outcomes for this complex patient population.
This consensus initiative offers several strengths. It provides real-world clinical insights from highly experienced critical care physicians managing complex VV-ECMO patients, a population for whom high-level evidence is often scarce. The use of a community peer-review platform lends a degree of validation to the discussed approaches, reflecting a collective clinical wisdom. The detailed protocols and specific patient scenario allow for direct applicability to similar clinical dilemmas. Furthermore, the synthesis integrates multiple facets of ECMO weaning, from cardiopulmonary assessment to adjunctive therapies and ancillary considerations like DVT screening, providing a comprehensive overview.
However, several limitations must be acknowledged. The primary limitation is the inherent nature of a consensus initiative derived from a clinical Q&A, which does not constitute a randomized controlled trial or a systematic review. The evidence presented, particularly for the use of inhaled iloprost and the specific durations of sweep trials, is largely based on expert opinion, institutional protocols, and anecdotal experience, rather than robust, high-quality evidence. Dr. Vasquez's cohort data, while informative, represents a small, single-center experience and may not be generalizable to all patient populations or institutions. The absence of long-term follow-up data for the decannulated patients, beyond 30-day RV normalization, also limits the assessment of sustained outcomes. Finally, the specific context of COVID-19 ARDS may introduce unique physiological considerations that might not apply universally to all ARDS etiologies.
Weaning from veno-venous extracorporeal membrane oxygenation (VV-ECMO) in patients with severe COVID-19 acute respiratory distress syndrome (ARDS) and persistent right ventricular (RV) dysfunction remains a multifaceted clinical challenge. This expert consensus initiative provides a pragmatic framework for navigating these complexities, emphasizing individualized patient assessment and a multidisciplinary approach.
The findings suggest that complete RV normalization is not an absolute prerequisite for successful decannulation; mild residual RV dysfunction may be acceptable if gas exchange and hemodynamic stability are maintained, with an expectation of post-ECMO RV recovery. Staged and prolonged sweep gas trials, coupled with comprehensive cardiopulmonary and hemodynamic monitoring, are crucial for safely assessing readiness for decannulation. The judicious use of inhaled pulmonary vasodilators, such as iloprost, may serve as a valuable bridging strategy for managing residual pulmonary hypertension.
Ultimately, successful VV-ECMO weaning necessitates a holistic approach, integrating advanced physiological monitoring, careful interpretation of imaging and biomarker data, and consideration of potential complications such as deep vein thrombosis. Further prospective, multicenter studies are warranted to standardize weaning protocols, validate the utility of adjunctive therapies, and optimize outcomes in this critically ill patient population.
Conceptualization: Elena Vasquez, Rajesh Iyer. Investigation: Elena Vasquez, Rajesh Iyer. Writing – Original Draft: Elena Vasquez. Writing – Review & Editing: Rajesh Iyer. Validation: Rajesh Iyer.
The authors declare no conflicts of interest related to this work.
No specific funding was received for this work.
Dr. Elena Vasquez, Dr. Rajesh Iyer. "Management of Right Ventricular Dysfunction and Weaning Protocols for Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19 Acute Respiratory Distress Syndrome: A Clinical Consensus Initiative." tachyDx Research, TDX-2026-00019, April 9, 2026. https://www.tachydx.com/research/TDX-2026-00019
This paper is indexed in the tachyDx Research Registry. DOI registration pending.
License: This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this material for any purpose, provided appropriate credit is given.
Disclaimer: tachyDx is a clinical knowledge synthesis platform currently in early access. The physician profiles and discussions shown are populated with real medical data to demonstrate platform functionality; contributor identities are presented for illustrative purposes and do not imply clinical endorsement. Content is AI-synthesized from peer-reviewed discussions and should not substitute professional medical advice.
No comments yet. Be the first verified physician to start the discussion.
Verified physicians can comment on published research.
Log in to comment